Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation

Aim. To assess the economic efficacy of a fixed combination tiotropium bromide+olodaterol (T+O) in comparison with other medications, included in the Vital and Essential Drugs List (VEDL), for the maintenance triple therapy of chronic obstructive pulmonary disease (COPD).

Materials and Methods. A Markov model was used for the estimation of direct medical costs associated with different medications. Costminimization and budget impact analyses were performed.

Results. The drug costs for T+O were the lowest among all compared treatment strategies. The cost savings in favor of T+O were 24.82% [15.86–29.95%]. The application of T+O strategy in 4,101 target patients led to a decrease in the total direct medical costs under the state programs of guarantees of free medical care by 13.13% in 3 years, which will make T+O therapy available to 643 more patients in the first year and 1,624 patients in three years.

Conclusion. A fixed combination T+O is a preferred efficient option for maintenance triple treatment for patients with COPD in comparison with other drugs from VEDL, because it is associated with lower total costs and equal efficacy.

1. Singh D. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. European Respiratory Journal. 2019; 53 5.

2. Informatsionnyi byulleten’ VOZ №135, dekabr’ 2017 g. [Electronic resource]. URL: https://www.who.int/ru/news-room/factsheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed: 10.12.2019.

3. Nedogoda S. V., Barykina I. N., Salasyuk A. S. et al. Pharmacoeconomic Analysis of Tiotropium Bromide and Olodat-erol Fixed Combination as Maintenance Therapy in Patients with Chronic Obstructive Pulmonary Disease in Russian Federation. Meditsinskie tekhnologii. Otsenka i vybor (in Russ). 2018; 2 (32): 81–93.

4. Chuchalin A. G. Chronic obstructive pulmonary disease. Moscow. 2011; 230–453.

5. Starodubov V. I., Leonov S. A., Vaisman D. Sh. Analysis of the main trends in morbidity from chronic obstructive pulmonary disease and bronchiectasis in the Russian Federation in 2005–2012 years. Meditsina (in Russ). 2013; 1 (4).

6. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014; 12: 963–74.

7. KR603. Clinical recommendations. Chronic obstructive pulmonary disease. 2018 g. URL: http://cr.rosminzdrav.ru/#!/recomend/908. Accessed: 10.12.2019. (in Russ).

8. Buhl R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). European Respiratory Journal. 2015; 45 (4): 969–979.

9. Beeh K.M. et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulmonary pharmacology & therapeutics. 2015; 32: 53–59.

10. Beeh K. M. et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twicedaily salmeterol and fluticasone propionate via Accuhaler®(ENERGITO® study). International journal of chronic obstructive pulmonary disease. 2016; 11 193.

11. Ferguson G. T. et al. Efficacy of tiotropium+olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Advances in therapy. 2015; 32 (6): 523–536.

12. Calverley P.M. A. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. The Lancet Respiratory Medicine. 2018; 6 (5): 337–344.

13. Maltais F. et al. Dose determination for a fixed-dose drug combination: a phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD. Advances in therapy. 2019; 36 (4): 962–968.

14. Maltais F. et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. European Respiratory Journal. 2019; 53 (3): 1802049.

15. O’Donnell D. E. et al. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. European Respiratory Journal. 2017; 49 (4).

16. Troosters T. et al. Effect of bronchodilation and exercise training with behavior modification on exercise tolerance and downstream effects on symptoms and physical activity in COPD. Am J Respir Crit Care Med. 2018; 198 (8): 1021–1032.

17. Singh D. et al. Tiotropium+ olodaterol shows clinically meaningful improvements in quality of life. Respiratory medicine. 2015; 109 (10): 1312–1319.

18. Gonzalez-Rojas N. Network meta-analysis for tiotropium+ olodaterol fixed dose combination in chronic obstructive pulmonary disease (COPD): Comparison with triple therapy. Final report. 2015 Nov. 20; 1–16. Boehringer Ingelheim AG & Ko KG data. 19. Suissa S., Dell’Aniello S., Ernst P. Comparative effects of LAMALABA-ICS versus LAMA-LABA for COPD: Cohort study in real world clinical practice: LAMA-LABA-ICS versus LAMA-LABA in COPD. Chest. 2019.

19. State register of maximum selling prices [Electronic resource] URL: https://grls.rosminzdrav.ru/pricelims.aspx. Accessed: 25.11.19.

20. Data on the maximum sizes of wholesale allowances and the maximum sizes of retail allowances to the prices of vital and essential medicines established in the constituent entities of the Russian Federation (data for the 4th quarter of 2018) [Electronic resource] URL: https://fas.gov.ru/documents/678638. Accessed: 10.03.2019.

21. Ministry of Health of the Russian Federation, Federal Fund for Compulsory Medical Insurance. Guidelines on methods of paying for medical care at the expense of compulsory medical insurance for 2019 (minutes of the meeting dated November 12, 2018 No. 66/11/15).

22. Decree of the Government of the Russian Federation “On the Program of State Guarantees for the Free Provision of Medical Assistance to Citizens for 2019 and for the Planning Period 2020 and 2021” (prepared by the Ministry of Health of Russia on December 10, 2018).

23. PrIndexTM study "Monitoring of medical prescription”. Ipsos COMCON LLC, 3rd quarter of 2019.